Impact of surotomycin on the gut microbiota of healthy volunteers in a phase 1 clinical trial

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2069-2074

  Citron, Diane M ^a   Tyrrell, Kerin L ^a   Dale, Suzanne E ^b   Chesnel, Laurent ^c   Goldsteina, Ellie J C ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b ACM Medical Laboratories   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUROTOMYCIN; ANTIINFECTIVE AGENT; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE;

ADULT; ARTICLE; BACTERIAL COUNT; BACTEROIDES; BIFIDOBACTERIUM; CLOSTRIDIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENTEROCOCCUS; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; LACTOBACILLUS; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PREVOTELLA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; BACTEROIDES FRAGILIS; CLINICAL TRIAL; DRUG EFFECTS; ENTEROBACTERIACEAE; FECES; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY;

ADULT; ANTI-BACTERIAL AGENTS; BACTEROIDES FRAGILIS; DOUBLE-BLIND METHOD; ENTEROBACTERIACEAE; ENTEROCOCCUS; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HEALTHY VOLUNTEERS; HUMANS; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PEPTIDES, CYCLIC; PREVOTELLA;

EID: 84963636160     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02531-15     Document Type: Article

References (32)

1. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197:435- 438. http://dx.doi.org/10.1086/525047.
2. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80:62- 73. http://dx.doi.org/10.1128/IAI.05496-11.
3. Buffie CG, Pamer EG. 2013. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 13:790-801. http://dx.doi.org/10.1038/nri3535.
4. He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, D'Arc S, Brazier J, Brown D, Coia JE, Douce G, Gerding D, Kim HJ, Koh TH, Kato H, Senoh M, Louie T, Michell S, Butt E, Peacock SJ, Brown NM, Riley T, Songer G, Wilcox M, Pirmohamed M, Kuijper E, Hawkey P, Wren BW, Dougan G, Parkhill J, Lawley TD. 2013. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 45:109- 113. http://dx.doi.org/10.1038/ng.2478.
5. Centers for Disease Control and Prevention (CDC). 2005. Severe Clostridium difficile-associated disease in populations previously at low risk- four states, 2005. MMWR Morb Mortal Wkly Rep 54:1201-1205.
6. McDonald LC, Owings M, Jernigan DB. 2006. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12:409-415.
7. Redelings MD, Sorvillo F, Mascola L. 2007. Increase in Clostridium difficile-related mortality rates, United States, 1999 -2004. Emerg Infect Dis 13:1417-1419. http://dx.doi.org/10.3201/eid1309.061116.
8. Burckhardt F, Friedrich A, Beier D, Eckmanns T. 2008. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis 14:691- 692http://dx.doi.org/10.3201/eid1404.071023.
9. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, Mulvey M, Canadian Nosocomial Infection Surveillance Program. 2009. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program study. Clin Infect Dis 48:568-576. http://dx.doi.org/10.1086/596703.
10. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile- Associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302-307. http://dx.doi.org/10.1086/519265.
11. Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. 2007. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102:2781-2788. http://dx.doi.org/10.1111/j.1572-0241.2007.01539.x.
12. Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, Hamill RJ. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40:1586-1590. http://dx.doi.org/10.1086/430311.
13. Mascio CTM, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA. 2012. In vitro and in vivo characterization of CB-183, 315, a novel lipopeptide antibiotic for the treatment of Clostridium difficile. Antimicrob Agents Chemother 56: 5023-5030. http://dx.doi.org/10.1128/AAC.00057-12.
14. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. In vitro activities of CB-183, 315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 56:1613-1615. http://dx.doi.org/10.1128/AAC.05655-11.
15. Snydman DR, Jacobus NV, McDermott LA. 2012. Activity of a novel cyclic lipopeptide, CB-183, 315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 56:3448-3452. http://dx.doi.org/10.1128/AAC.06257-11.
16. Patino H, Stevens C, Louie T, Bernardo P, Friedland I. 2011. Efficacy and safety of the lipopeptide CB-183, 315 for the treatment of Clostridium difficile infection, abstr K-205a. Abstr 51st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
17. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52:2403- 2406. http://dx.doi.org/10.1128/AAC.00090-08.
18. Nadkarni MA, Martin FE, Jacques NA, Hunter N. 2002. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 148:257-266. http://dx.doi.org/10.1099/00221287-148-1-257.
19. Bernhard AE, Field KG. 2000. Identification of nonpoint sources of fecal pollution in coastal waters by using host-specific 16S ribosomal DNA genetic markers from fecal anaerobes. Appl Environ Microbiol 66:1587- 1594. http://dx.doi.org/10.1128/AEM.66.4.1587-1594.2000.
20. Loy A, Maixner F, Wagner M, Horn M. 2007. probeBase-an online resource for rRNA-targeted oligonucleotide probes: new features 2007. Nucleic Acids Res 35:D800-D804. http://dx.doi.org/10.1093/nar/gkl856.
21. Bartosch S, Fite A, MacFarlane GT, McMurdo ME. 2004. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Appl Environ Microbiol 70:3575- 3581. http://dx.doi.org/10.1128/AEM.70.6.3575-3581.2004.
22. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Hookman P, Barkin JS. 2009. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 15:1554-1580. http://dx.doi.org/10.3748/wjg.15.1554.
25. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55(Suppl 2):S132- S142. http://dx.doi.org/10.1093/cid/cis338.
26. Hurless K, Cadnum JL, Chesnel L, Deshpande A, Donskey CJ. 2013. Effect of surotomycin, a novel cyclic lipopeptide antibiotic, on intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice, poster F628. Abstr 53rd Annu Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
27. Cannon K, Byrne B, Happe J, Louie T. 2012. Enteric microbiome profiles during a phase 2 clinical trial of CB-183, 315 or vancomycin for treatment of Clostridium difficile infection. Clin Microbiol Infect 18(Suppl 3):659.
28. Chesnel L, Sambol S, Gerding D, Patino H, Therne G, Silverman J. 2012. Treatment of CDAD with oral CB-183 315: Time to recurrence, relapse and re-infection rates compared with vancomycin. Clin Microbiol Infect 18(Suppl 3):380.
29. Fujitani S, George WL, Morgan MA, Nichols S, Murthy AR. 2011. Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections. Am J Infect Control 39:188-193. http://dx.doi.org/10.1016/j.ajic.2010.10.024.
30. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 55(Suppl 2):S121-S126. http://dx.doi.org/10.1093/cid/cis440.
31. Ubeda C, Taur Y, Jeng RR, Equinda MJ, Son T, Samstein M, Viale A, Socci ND, van den Brink MR, Kamboj M, Pamer EG. 2010. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes blood stream invasion in humans. J Clin Invest 120:4332-4341. http://dx.doi.org/10.1172/JCI43918.
32. Mascio CT, Chesnel L, Thorne G, Silverman JA. 2014. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis and Enterococcus faecium. Antimicrob Agents Chemother 58:3976-3982. http://dx.doi.org/10.1128/AAC.00124-14.